Piper Sandler analyst David Westenberg reiterated an Overweight rating and $130.00 price target on GeneDx (NASDAQ: WGS).

The analyst commented: "While we admit GeneDx's earnings set-up isn't perfect, we do believe they'll land roughly in line with volume guidance setting up a back half weighted 2026. This year and out-year revenue estimates are up meaningfully since the Q3 2025 print, and yet, the stock is down over 60%. This suggests to us the stock is going to find a valuation floor. Meanwhile, checks with docs remain positive. We hosted a call with a doc last week who confirmed the bull thesis of expanding testing and a moat around being a first mover. We reiterate OW."

For an analyst ratings summary and ratings history on GeneDx click here. For more ratings news on GeneDx click here.

Shares of GeneDx closed at $59.61 yesterday.